Leadership Team

D. Keith Grossman joined us in March 2019 and served as our CEO and President from March 2019 to April 2023. Following his retirement as Chief Executive Officer and President, he was appointed to serve as Executive Chairman of the Board of Nevro, then in October of 2023 transitioned to the role of Non-Executive Chairman of the Board. Mr. Grossman has over 35 years of experience in the medical device field. Prior to Nevro, he was named President, CEO and Director of Thoratec Corp. for the second time in 2014, leading up to its 2015 sale to St. Jude Medical. Prior to Thoratec, he served as President, CEO and director of Conceptus, a women’s health medical device company, leading up to its sale to Bayer Healthcare. Prior to Conceptus, Mr. Grossman served as managing director of TPG (Texas Pacific Group), a private equity firm, as a member of its healthcare investment team. Prior to TPG, Mr. Grossman served as Thoratec’s President, CEO and director for the first ten years of its growth as a commercial company. Mr. Grossman currently serves as Vice Chairman of Alcon, Inc. and as Lead Independent Director of Outset Medical, Inc. and previously served as a member of the Board of Directors of Intuitive Surgical, Inc., Kyphon, Inc., ViewRay, Inc., Zeltiq, Inc and a number of privately held medical device companies. Mr. Grossman received a B.S. in life sciences from The Ohio State University and an M.B.A. from Pepperdine University.

Michael DeMane joined us in March 2011 and has served as our Chief Executive Officer and as Executive Chairman. Effective January 1, 2017, Mr. DeMane transitioned to non-executive Chairman of the Board. Mr. DeMane has served on the board of directors of several private companies since 2009, as well as on the board of directors of eResearch Technology, Inc., a public company specializing in contract research clinical services, from July 2008 to April 2012. From March 2009 to June 2010, Mr. DeMane served as a Senior Advisor to Thomas, McNerney & Partners, a healthcare venture firm. Mr. DeMane served as the Chief Operating Officer of Medtronic from August 2007 to April 2008. Prior to his COO role, Mr. DeMane served at Medtronic as Senior Vice President from May 2007 to August 2007, Senior Vice President and President: Europe, Canada, Latin America and Emerging Markets from August 2005 to May 2007, Senior Vice President and President: Spinal, ENT and Navigation from February 2002 to August 2005, and President, Spinal from January 2000 to February 2002. Prior to that, he was President at Interbody Technologies, a division of Medtronic Sofamor Danek, Inc., from June 1998 to December 1999. From April 1996 to June 1998, Mr. DeMane served at Smith & Nephew Pty. Ltd. as Managing Director, Australia and New Zealand, after a series of research and development and general management positions with Smith & Nephew Inc. Mr. DeMane earned a B.S. in Chemistry from St. Lawrence University and an M.S. in Bioengineering from Clemson University.

Sri Kosaraju has served on our Board since August 2021. Since October 2020, Mr. Kosaraju has served as the Chief Executive Officer and President of Inscripta, Inc., a privately-held digital genome engineering company. Prior to joining Inscripta, Mr. Kosaraju was President of Penumbra, Inc., which he joined as CFO in May 2015. Earlier, Mr. Kosaraju spent 16 years at J.P. Morgan, where he was most recently Head of Healthcare Equity Capital Markets and Co-Head of Technology Equity Capital Markets. While at J.P. Morgan, he worked closely with and advised many emerging, high-growth life science and tech companies. In addition to serving on the Board of Directors for Inscripta, Mr. Kosaraju also currently serves on the Board of Directors and is the Chair of the Audit Committee of 10x Genomics, Inc., a life science technology company building products to interrogate, understand and master biology to advance human health, and is on the Board of the non-profit Testing for America. Mr. Kosaraju earned his B.S in Mechanical Engineering from the Massachusetts Institute of Technology (MIT).

Shawn T McCormick has served on our Board since September 2014. From November 2020 to February 2022, Mr. McCormick served as Chief Financial Officer of Aldevron, a privately held company and global leader in the manufacture of plasmid DNA, mRNA and proteins. Aldevron was acquired by Danaher in August 2021. Mr. McCormick served as Chief Financial Officer of Tornier N.V., a public medical device company (“Tornier”), from September 2012 to October 2015 when Tornier merged with Wright Medical Group. From April 2011 to February 2012, Mr. McCormick was Chief Operating Officer of Lutonix, Inc., a medical device company acquired by C. R. Bard, Inc. in December 2011. From January 2009 to July 2010, Mr. McCormick served as Senior Vice President and Chief Financial Officer of ev3 Inc., a public endovascular device company acquired by Covidien plc in July 2010. From 2002 to 2009, Mr. McCormick held various senior leadership positions at Medtronic Inc., including Vice President of Finance for Medtronic’s Spinal, Biologics, and Navigation business, Vice President, Corporate Technology and New Ventures and Vice President, Corporate Development. Prior to that, Mr. McCormick held various other positions with Medtronic, including Corporate Development Director, Principal Corporate Development Associate, Manager, Financial Analysis, Senior Financial Analyst and Senior Auditor. Prior to joining Medtronic, he spent four years with the public accounting firm KPMG Peat Marwick. Mr. McCormick has been a director of Inspire Medical Systems, Inc., a public medical technology company focused on minimally invasive solutions for patients with obstructive sleep apnea, since January 2017 and serves as chair of the audit committee. He was a director of SurModics, Inc., a public medical device and in vitro diagnostic technologies company, and served on the audit committee and corporate governance and nominating committee from December 2015 to December 2020. He was also a director of Entellus Medical, Inc., a public medical device company, and served as the chairman of the audit committee and as a member of the nominating and corporate governance committee from November 2014 to February 2018 when Entellus was sold to Stryker. Mr. McCormick earned his M.B.A. from the University of Minnesota’s Carlson School of Management and his B.S. in Accounting from Arizona State University. He is a Certified Public Accountant (inactive license).

Kevin O'Boyle has served on our Board since March 2019. Mr. O’Boyle has over 20 years of executive management experience in the medical device industry. Mr. O’Boyle currently serves as a director of GenMark Diagnostics, Inc. and Sientra, Inc. Previously, Mr. O’Boyle served as Senior Vice President and Chief Financial Officer of Advanced Biohealing Inc. a medical device company, from December 2010 until it was acquired in July 2011. Mr. O’Boyle served as CFO of NuVasive, Inc. from January 2003 until December 2009. Prior to that, Mr. O’Boyle served in various leadership positions during his six years with ChromaVision Medical Systems, Inc. Mr. O’Boyle received a B.S. in Accounting from the Rochester Institute of Technology and completed the Executive Management Program at the University of California Los Angeles, John E. Anderson Graduate Business School.

Karen Prange has served on our board since December 2019. Ms. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein and a member of its Executive Committee. In this role, she led a business that generated over $6 billion of revenue across three different business units, growing the business to above-market levels in all business segments. Prior to her role at Henry Schein, she was Senior Vice President of Boston Scientific and President of its Urology and Pelvic Health business and served as General Manager of the Micrus Endovascular and Codman Neurovascular business at Johnson & Johnson Company. In addition to general management roles, Ms. Prange has extensive experience in commercial and operational roles, including managing innovation pipelines and acquiring and integrating companies. Ms. Prange currently serves on the boards of Atricure, ViewRay Inc. and WS Audiology. She also serves as Strategic Advisor to Nuvo Group Ltd. and Industrial Advisor to EQT Group. Ms. Prange earned her B.S. in Business Administration with honors from University of Florida and has completed executive education coursework at UCLA Anderson School of Business and Smith College.

Sue Siegel has served on our board since December 2020. Previously, Ms. Siegel served as GE’s Chief Innovation Officer, CEO of GE Ventures & Licensing, and CEO of Healthymagination. Before GE, she was a VC General Partner at Mohr Davidow Ventures, leading investments in Life Sciences & Health. During the early days of the human genome project, Ms. Siegel led Affymetrix from a pre-revenue start up to a multi-billion publicly-listed company that helped shape the emerging genomics industry. Ms. Siegel earned her B.S. in Biology from the University of Puerto Rico – Mayaguez and her M.S. in Biochemistry and Molecular Biology from Boston University School of Medicine. Ms. Siegel currently serves on the boards of Illumina, Align Technology, the Kaiser Family Foundation, and is Chairman of the Board of Directors of MIT’s The Engine.

Kevin Thornal was named CEO and President of Nevro in April of 2023. He will also be appointed to the Nevro Board of Directors. Mr. Thornal has over 20 years of senior management experience, including nearly nine years at Hologic, Inc., where he most recently served as Group President, Global Diagnostic Solutions, since April 2022. Under Kevin’s leadership, this group of businesses delivered above-market revenue growth rates, achieving about $2.9 billion in worldwide diagnostics sales including the impact of COVID testing revenue. Mr. Thornal joined Hologic in 2014 as Vice President, Customer Experience, Field Service and Clinical Applications for the Breast and Skeletal Health division. He transitioned to Vice President, Breast and Skeletal Health for the Europe, Middle East and Africa region in early 2016, and was promoted to President, Medical Aesthetics in July 2017. In July 2019, he was promoted to President, Diagnostic Solutions where he led the division during the COVID-19 pandemic, rapidly launching three highly accurate molecular diagnostic COVID-19 tests in the fight against the global pandemic, and leading multiple acquisitions. Prior to Hologic, he held various roles of increasing responsibility at Stryker from 2004 to 2014 in sales, marketing, and business development. Mr. Thornal received a B.A. in History, with minors in English and Secondary Education, from Southern Methodist University.

Bess Weatherman joined us in March 2019 and currently serves as a member of our Board. Ms. Weatherman has served as special limited partner of Warburg Pincus LLC, a leading global private equity firm, since 2016. Ms. Weatherman joined Warburg Pincus in 1988, became a partner in 1996 and served as a member of the Executive Management Group from 2001 to January 2016. She led the firm’s Healthcare Group from 2008 to January 2015. Ms. Weatherman currently serves as a director of Insulet Corporation, Silk Road Medical, Inc., and Vapotherm, Inc. She received a B.A. in English from Mount Holyoke College and an M.B.A. from Stanford Graduate School of Business.